LOSS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of basic and diluted earnings (loss) per share

	Three Months Ended March 31,
	2020			2019
Basic and Diluted
Net loss attributable to American Renal Associates Holdings, Inc.	$	(7,234	)	$	(10,479	)
Change in the difference between the redemption value and estimated fair value for accounting purposes of the related noncontrolling interests	(258		)	(741		)
Net loss attributable to common shareholders	$	(7,492	)	$	(11,220	)
Weighted‑average common shares outstanding, basic	32,459,792			32,187,715
Weighted‑average common shares outstanding, assuming dilution	32,459,792			32,187,715
Loss per share, basic and diluted	$	(0.23	)	$	(0.35	)
Outstanding options and restricted stock excluded as impact would be anti-dilutive	3,469,001			3,573,305